Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression

Behavioural Brain Research

Volumn 225, Issue 1, 2011, Pages 243-251

  Bah, Thierno Madjou ^a,b   Benderdour, Mohamed ^a,b   Kaloustian, Sévan ^a,b   Karam, Ramy ^a   Rousseau, Guy ^a,b   Godbout, Roger ^a,b  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antidepressant; Corticosterone; Cytokines; Myocardial infarction; Paradoxical sleep; Prostaglandin

Indexed keywords

CORTICOSTERONE; CYTOKINE; ESCITALOPRAM; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; FORCED SWIMMING TEST; HEART INFARCTION; HEART INFARCTION SIZE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; OSMOTIC MINIPUMP; POSTCARDIAC INFARCTION DEPRESSION; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; RAT; REM SLEEP; SLEEP; SLEEP TIME; TASTE PREFERENCE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOOD PREFERENCES; MALE; MYOCARDIAL INFARCTION; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; SLEEP STAGES; SUCROSE; SWEETENING AGENTS; SWIMMING;

EID: 80051633732     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.07.039     Document Type: Article

References (88)

1. Guck T.P., Kavan M.G., Elsasser G.N., Barone E.J. Assessment and treatment of depression following myocardial infarction. Am Fam Physician 2001, 64:641-648.
2. Frasure-Smith N., Lesperance F. Depression and other psychological risks following myocardial infarction. Arch Gen Psychiatry 2003, 60:627-636.
3. Frasure-Smith N., Lesperance F., Gravel G., Masson A., Juneau M., Talajic M., et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation 2000, 101:1919-1924.
4. Lane D., Carroll D., Ring C., Beevers D.G., Lip G.Y. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001, 63:221-230.
5. Bah T.M., Laplante F., Wann B., Sullivan R., Rousseau G., Godbout R. Paradoxical sleep insomnia and decreased cholinergic neurons after myocardial infarction in the rats. Sleep 2010, 33:1703-1710.
6. Wann B.P., Bah T.M., Boucher M., Courtemanche J., Le Marec N., Rousseau G., et al. Vulnerability for apoptosis in the limbic system after myocardial infarction in rats: a possible model for human postinfarct major depression. J Psychiatry Neurosci 2007, 32:11-16.
7. Wann B.P., Bah T.M., Kaloustian S., Boucher M., Dufort A.M., Le Marec N., et al. Behavioural signs of depression and apoptosis in the limbic system following myocardial infarction: effects of sertraline. J Psychopharmacol 2009, 23:451-459.
8. Wann B.P., Boucher M., Kaloustian S., Nim S., Godbout R., Rousseau G. Apoptosis detected in the amygdala following myocardial infarction in the rat. Biol Psychiatry 2006, 59:430-433.
9. Kaloustian S., Wann B.P., Bah T.M., Girard S.A., Apostolakis A., Ishak S., et al. Apoptosis time course in the limbic system after myocardial infarction in the rat. Brain Res 2008, 1216:87-91.
10. Kaloustian S., Wann B.P., Bah T.M., Falcao S., Dufort A.M., Ryvlin P., et al. Celecoxib after the onset of reperfusion reduces apoptosis in the amygdala. Apoptosis 2007, 12:1945-1951.
11. Rondeau I., Picard S., Bah T.M., Roy L., Godbout R., Rousseau G. Effects of different dietary omega-6/3 polyunsaturated fatty acids ratios on infarct size and the limbic system after myocardial infarction. Can J Physiol Pharmacol 2011, 89:169-176.
12. Girard S.A., Bah T.M., Kaloustian S., Lada-Moldovan L., Rondeau I., Tompkins T.A., et al. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br J Nutr 2009, 102:1420-1425.
13. Kaloustian S., Bah T.M., Rondeau I., Mathieu S., Lada-Moldovan L., Ryvlin P., et al. Tumor necrosis factor-alpha participates in apoptosis in the limbic system after myocardial infarction. Apoptosis 2009, 14:1308-1316.
14. Grippo A.J., Francis J., Weiss R.M., Felder R.B., Johnson A.K. Cytokine mediation of experimental heart failure-induced anhedonia. Am J Physiol Regul Integr Comp Physiol 2003, 284:R666-R673.
15. Craddock D., Thomas A. Cytokines and late-life depression. Essent Psychopharmacol 2006, 7:42-52.
16. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
17. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
18. Bareggi S.R., Mundo E., Dell'Osso B., Altamura A.C. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 2007, 3:741-753.
19. Basterzi A.D., Aydemir C., Kisa C., Aksaray S., Tuzer V., Yazici K., et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005, 20:473-476.
20. Höschl C., Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother 2008, 8:537-552.
21. Kapsimalis F., Richardson G., Opp M.R., Kryger M. Cytokines and normal sleep. Curr Opin Pulm Med 2005, 11:481-484.
22. Kubera M., Simbirtsev A., Mathison R., Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res 2000, 96:255-266.
23. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol 2001, 16:95-103.
24. Giulian D. Primer on cerebrovascular disease 1997, Academic Press, San Diego, CA, USA.
25. Stahl S., Gergel I., Dayong L. Escitalopram in the treatment of panic disorder: a randomized double-blind, placebo controlled trial. J Clin Psychiatry 2003, 64:1322-1327.
26. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
27. West A.P. Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry 1990, 14:863-877.
28. Redei E.E., Ahmadiyeh N., Baum A.E., Sasso D.A., Slone J.L., Solberg L.C., et al. Novel animal models of affective disorders. Semin Clin Neuropsychiatry 2001, 6:43-67.
29. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.
30. Field A. Discovering statistics using SPSS 2009, SAGE Edition. 3rd ed.
31. Boucher M., Pesant S., Falcao S., de Montigny C., Schampaert E., Cardinal R., et al. Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway. J Cardiovasc Pharmacol 2004, 43:416-422.
32. Hausenloy D.J., Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004, 61:448-460.
33. Nebigil C.G., Etienne N., Messaddeq N., Maroteaux L. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B receptor signaling. FASEB J 2003, 17:1373-1375.
34. Kusmider M., Solich J., Palach P., Dziedzicka-Wasylewska M. Effect of citalopram in the modified forced swim test in rats. Pharmacol Rep 2007, 59:785-788.
35. Porsolt R.D., Bertin A., Jalfre M. " Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 1978, 51:291-294.
36. El Khoury A., Gruber S.H., Mork A., Mathe A.A. Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:535-540.
37. López-Rubalcava C., Lucki I. Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology 2000, 22:191-199.
38. Piubelli C., Vighini M., Mathe A.A., Domenici E., Carboni L. Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: Genetic background. Int J Neuropsychopharmacol 2010, 1-38.
39. Grippo A.J., Beltz T.G., Weiss R.M., Johnson A.K. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry 2006, 59:309-316.
40. Moreau J.L. Validation of an animal model of anhedonia, a major symptom of depression. Encephale 1997, 23:280-289.
41. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997, 134:319-329.
42. Rygula R., Abumaria N., Flugge G., Fuchs E., Ruther E., Havemann-Reinecke U. Anhedonia and motivational deficits in rats: impact of chronic social stress. Behav Brain Res 2005, 162:127-134.
43. Overstreet D.H. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 1993, 17:51-68.
44. Abad V.C., Guilleminault C. Sleep and psychiatry. Dialogues Clin Neurosci 2005, 7:291-303.
45. Benca R.M. Sleep in psychiatric disorders. Neurol Clin 1996, 14:739-764.
46. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005, 29:627-647.
47. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52:90-110.
48. Adrien J., Dugovic C., Martin P. Sleep-wakefulness patterns in the helpless rat. Physiol Behav 1991, 49:257-262.
49. Vogel G., Neill D., Hagler M., Kors D. A new animal model of endogenous depression: a summary of present findings. Neurosci Biobehav Rev 1990, 14:85-91.
50. Overstreet D.H., Friedman E., Mathe A.A., Yadid G. The Flinders sensitive line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005, 29:739-759.
51. Hicks J.A., Argyropoulos S.V., Rich A.S., Nash J.R., Bell C.J., Edwards C., et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002, 180:528-535.
52. Jindal R.D., Friedman E.S., Berman S.R., Fasiczka A.L., Howland R.H., Thase M.E. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol 2003, 23:540-548.
53. Sanchez C., Brennum L.T., Storustovu S., Kreilgard M., Mork A. Depression and poor sleep: the effect of monoaminergic antidepressants in a pre-clinical model in rats. Pharmacol Biochem Behav 2007, 86:468-476.
54. BaHammam A. Sleep quality of patients with acute myocardial infarction outside the CCU environment: a preliminary study. Med Sci Monit 2006, 12:CR168-CR172.
55. Broughton R., Baron R. Sleep patterns in the intensive care unit and on the ward after acute myocardial infarction. Electroencephalogr Clin Neurophysiol 1978, 45:348-360.
56. Schiza S.E., Simantirakis E., Bouloukaki I., Mermigkis C., Arfanakis D., Chrysostomakis S., et al. Sleep patterns in patients with acute coronary syndromes. Sleep Med 2010, 11:149-153.
57. Cartwright R.D., Wood E. Adjustment disorders of sleep: the sleep effects of a major stressful event and its resolution. Psychiatry Res 1991, 39:199-209.
58. Mendlewicz J. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry 2009, 10:269-275.
59. Connor T.J., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998, 62:583-606.
60. Nito I., Waspadji S., Harun S., Markum H.M. Correlation between cortisol levels and myocardial infarction mortality among intensive coronary care unit patients during first seven days in hospital. Acta Med Indones 2004, 36:8-14.
61. Leonard B.E. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:767-780.
62. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 2009, 34:4-20.
63. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat Med 2001, 7:541-547.
64. Calabresi L., Rossoni G., Gomaraschi M., Sisto F., Berti F., Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003, 92:330-337.
65. Berger H.J., Zaret B.L., Speroff L., Cohen L.S., Wolfson S. Regional cardiac prostaglandin release during myocardial ischemia in anesthetized dogs. Circ Res 1976, 38:566-571.
66. Laflamme N., Lacroix S., Rivest S. An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 1999, 19:10923-10930.
67. Berk M., Wadee A.A., Kuschke R.H., O'Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res 1997, 43:529-534.
68. Maes M., Scharpe S., Meltzer H.Y., Bosmans E., Suy E., Calabrese J., et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993, 49:11-27.
69. Kagaya A., Kugaya A., Takebayashi M., Fukue-Saeki M., Saeki T., Yamawaki S., et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 2001, 43:59-62.
70. Levine J., Barak Y., Chengappa K.N., Rapoport A., Rebey M., Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40:171-176.
71. Deten A., Volz H.C., Briest W., Zimmer H.G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002, 55:329-340.
72. Nan B., Getchell M.L., Partin J.V., Getchell T.V. Leukemia inhibitory factor, interleukin-6, and their receptors are expressed transiently in the olfactory mucosa after target ablation. J Comp Neurol 2001, 435:60-77.
73. Desbonnet L., Garrett L., Clarke G., Kiely B., Cryan J.F., Dinan T.G. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 2010, 170:1179-1188.
74. Li S., Wang C., Wang W., Dong H., Hou P., Tang Y. Chronic mild stress impairs cognition in mice: from brain homeostasis to behavior. Life Sci 2008, 82:934-942.
75. Goodwin G.M. Tricyclic and newer antidepressants. Handbook of affective disorders 1992, Churchill Livingstone, Edinburgh/London/Madrid/Melbourne/New York/Tokyo. E.S. Paykel (Ed.).
76. Gram L.F. Fluoxetine. N Engl J Med 1994, 17:1354-1361.
77. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996, 177:187-205.
78. Seckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992, 55:621-626.
79. Sulser F. New perspectives on the molecular pharmacology of affective disorders. Eur Arch Psychiatr Neurol Sci 1989, 238:231-239.
80. Spanova A., Kovaru H., Lisa V., Lukasova E., Rittich B. Estimation of apoptosis in C6 glioma cells treated with antidepressants. Physiol Res 1997, 161-164.
81. Xia Z., Depierre J.W., Nassberger L. The tricyclic antidepressants clomipramine and citalopram induce apoptosis in cultured human lymphocytes. J Pharm Pharmacol 1996, 48:115-116.
82. Xia Z., DePierre J.W., Nassberger L. Modulation of apoptosis induced by tricyclic antidepressants in human peripheral lymphocytes. J Biochem Mol Toxicol 1998, 12:115-123.
83. Xia Z., Lundgren B., Bergstrand A., DePierre J.W., Nassberger L. Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Biochem Pharmacol 1999, 57:1199-1208.
84. Jin Y., Lim C.M., Kim S.W., Park J.Y., Seo J.S., Han P.L., et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 2009, 1281:108-116.
85. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56:819-824.
86. Simmons D.A., Broderick P.A. Cytokines, stressors, and clinical depression: augmented adaptation responses underlie depression pathogenesis. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:793-807.
87. Tucker P., Ruwe W.D., Masters B., Parker D.E., Hossain A., Trautman R.P., et al. Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol Psychiatry 2004, 56:121-128.
88. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007, 41:326-331.